cardiovascular disease locally has not matched its growth.
INTRODUCTION
The global burden of disease is shifting from communicable to non-communicable disease. Without intervention, the morbidity due to cardiovascular diseases will likely supersede human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) come 2030. (1) (2) (3) More than 80% of cardiovascular-related deaths are estimated to occur in low-to middle-income countries (LMICs) despite a dearth of cardiovascular disease knowledge in sub-Saharan Africa.
( [1] [2] [3] [4] [5] Acute coronary syndrome (ACS) is the most common cause of death and disability among cardiovascular diseases. (3, 5, 6) Aggressive prevention strategies and treatment of ACS in high-income countries have yielded positive results with the resulting treatment reference standards having also been considered in LMICs. (5) However, the epidemiology, precise patterns and outcomes of ACS management in Africa remain poorly documented. (2, 7, 8) In LMICs -South Africa included -an increase of ACS appears to be largely due to transformational economic and lifestyle changes. (5, 8, 9) The INTERHEART study, one of the larger African studies on ischaemic heart disease, showed that risk factors in patients with ACS were similar to what had been documented in more developed settings, and smaller studies have replicated these findings. (4, (7) (8) (9) (10) (11) However, these studies have also shown a trend towards a younger mortality cohort. (4, 10, 12) More importantly though, addressing
102
Describing suspected non ST-elevation acute coronary syndrome using troponin at a regional, public South African emergency centre with the Roche cardiac reader
TROPONIN AND NON-ST ELEVATION ACS
Volume 15 Number 2 sensitivity cardiac troponins has become the reference standard for the diagnosis of myocardial infarction, alongside risk stratification for ACS. (14) (15) (16) (17) Troponin assays use monoclonal antibodies to specifically detect either the troponin T or I. The accepted reference standard for the upper reference limit of a troponin assay is currently considered at the 99th percentile with a coefficient of variability of less than 10%. (14) (15) (16) (18) (19) (20) Importantly, as newer troponin assays (or high sensitivity troponin assays) continue to become more and more sensitive (and thus able to detect lower and lower levels of biomarker), the diagnosis of NSTEMI increases, with that of unstable angina becoming less common; perhaps only about 5% -10% of ACS cases are currently described as unstable angina as a result of high sensitivity troponin assays. (21) (22) (23) In contrast, the Thrombolysis in Myocardial Infarction-3 study showed that 25% of unstable angina patients diagnosed using a negative CK-MB (as part of the older definition of myocardial infarction), turned out to have a positive troponin. (22) This is a notable point, as compared to unstable angina, NSTEMI is associated with an increased risk of mortality and adverse cardiac outcomes. (18) Unfortunately, the downside of a more sensitive assay includes an increase in falsely elevated troponins, i.e. raised troponin for non-ACS related pathology (or a false positive finding). To ensure the correct diagnosis is made, current reference guidance recommends serial troponin testing to reduce the proportion of false positives. (15, 19, 24, 25) A significant change in troponin level of equal to, or more than, 20% from the baseline over a specified timeframe confirms an infarct. (15) Although very little is known about the use of troponin testing in LMICs, many local emergency centres still make use of troponin assays that do not adhere to current reference standards. Sadly, this fact remains anecdotal as the specific type of assay used at various LMIC emergency centres is poorly documented. It is unclear how the use of less sensitive troponin assays with a wider coefficient of variability stack up to an acceptably, safe diagnosis, or how these assays would function within clinical decision rules that require more sensitive results -both over and under-diagnosis of ACS will carry at least some risk of harm. (13, 17, 24) The site where this study took place makes use of such an assay, as does many centres throughout South Africa. Understanding how this diagnostic test relates to the diagnostic work-up and outcome of suspected ACS is therefore an important quality consideration locally.
The aim of this study was to describe the troponin result on first assessment in undifferentiated chest pain patients that attended a district, public emergency centre with suspected NSTE-ACS, and to compare this with whether NSTE-ACS was subsequently diagnosed (or not), as well as the outcome (admission or discharge to/from the hospital locally, transfer to tertiary centre, or death at the hospital locally).
MATERIALS AND METHODS
The study was performed using a retrospective, cross-sectional Hospital. The standard treatment guidance for NSTE-ACS is described in the local, provincial emergency care guidance. (27) The troponin assay used by Mitchell's Plain hospital's laboratory is the Roche CARDIAC ® T Quantitative assay, or Cardiac
Reader. We used the National Health Laboratory Service If the repeat troponin T assay remains between 50 and 100ng/L, the result is considered negative and if it rises above 100ng/L it is considered positive (thus dichotomising this finding). (27) Although a point of care assay, the test itself was performed in the laboratory by technicians and clinical staff were not involved in the testing or quality control process.
For the purpose of this study we were particularly interested in the NSTE-ACS cohort (NSTEMI and unstable angina), although instances of STEMI were also reported. It was assumed that STEMI data would be incomplete given the search strategy (STEMI is largely an ECG diagnosis in a particular clinical setting), hence the focus away from the STEMI cohort. As per local emergency centre guidance, patients suspected of NSTE-ACS are required to have a troponin test performed as part of their diagnostic workup. (27) We could therefore reliably identify study The exit diagnosis was taken from the clinical record and were described on death, discharge, or transfer from the emergency centre or hospital. Either a specialist physician or emergency physician would have been involved in deriving the exit diagnosis. Resources did not allow for the ECG to be specifically evaluated as part of the study protocol. This is further discussed in the limitations section. For the purposes of this study, where multiple troponin T tests were performed during a single admission, the first troponin T result taken 6 -12 hours after symptom onset (or admission in case symptom onset was not adequately described) was used to describe the result. Repeat troponins are encouraged in the local emergency care guidance, although non-consistently practiced. (27) Exclusions from the sample were for missing diagnosis and outcome variables.
Patients were not excluded for missing risk factor variables, and instead calculations were adapted to accommodate for missing variables.
A sample size of 384 consecutive subjects meeting the inclu- p<0.001). Admission to a ward and mortality showed no statistical difference, irrespective of whether the troponin result was positive or negative (p=0.54 and p=0.06, respectively). Table I describes the number and proportion of comorbidities for the study population and Table II describes the odds ratios from the univariate logistic regression analysis.
DISCUSSION
As far as we are aware this is the first observational study on this topic described in a South African, public sector, emergency centre population. The study showed that ACS was diagnosed in about a quarter of all patients included in the study popula- Admittedly the present study was not designed to assess the accuracy of the assay, however, the large unstable angina cohort presented here cannot simply be ignored either. As explained earlier, NSTEMI has a less favourable cardiac adverse event outlook compared to unstable angina; more sensitive troponin testing has allowed us to describe both appropriately. (18, 22) Unfavourable outcomes, of course, would occur whether NSTEMI is occult or not. Although it was not our intention to collect data on STEMI patients, some were invariably included in the study as part of the data collection strategy. Of note is the troponin negative STEMI cohort. There could be many reasons why STEMI patients would be associated with a negative troponin: early presentation, misdiagnosis and use of a less sensitive assay, to name but a few. A number of patients that presented with an elevated troponin were due to non-ACS causes. The study design did not describe these diagnoses in detail, however, there are a number of conditions described in the literature that can result in a troponin rise that is not considered ACS. (17) (18) (19) It would be interesting to describe this cohort in more detail in future research.
Given the significant associations with a number of reported risk factors, it is likely that the NSTE-ACS diagnosis relied substantially on an interpretation of risk factors and ECG findings in addition to troponin findings. The current study did not specifically evaluate ECG patterns commonly associated with ACS due to limited study resources, but rather relied on the exit diagnosis which usually involves either a specialist physician or an emergency physician. The findings from this study reenforce those of the INTERHEART study as both show an association of NSTE-ACS to a number of known risk factors. (14) It was interesting to note that diabetes was equally common among ACS and non-ACS patients and this finding may need further review in future research. It is disappointing that documentation of risk factors was so poor. Risk factors are particularly important in this study setting given the concern about the accuracy of the troponin assay.
From a high-income country perspective, the current value of troponin testing in the emergency centre rests in its ability to rule-out NSTE-ACS, since the vast majority of patients presenting with a suspected diagnosis of ACS turn out to not have the disease. What is concerning is that local clinicians' interpretations of troponin results are likely based on, and influenced by, international reference standards and risk assessment scores (such as the HEART score) that would not apply given a less sensitive troponin assay. (25, 27) Hypothetically, patients that are diagnosed as non-ACS on the basis of a false negative troponin result may come to harm from under-diagnosis. Likewise, over-diagnosis of ACS due to compensation for a flawed troponin assay will also be associated with an increased risk of harm (e.g. anticoagulation, missed alternative diagnosis, etc.).
A further disadvantage of the assay is the presentation of a range for a finding that should really be more easily dichotomised -using a range as wide as presented by the Cardiac
Reader renders serial testing flawed as clinically important changes in troponin level may occur without detection. (14, 19) It the value of a thorough history and physical examination when ACS is suspected; that a negative troponin should only be considered truly negative after close evaluation of a patient's symptoms, the history and ECG findings and that serial troponin testing is not necessarily a panacea when a range is presented instead of an absolute value. Evaluation of the diagnostic process in a multi-centre emergency care setting, particularly focusing on the contribution of ECG findings and the 30-day major adverse cardiac event rate, should be encouraged in order to strengthen a case for better diagnostic tools for LMIC emergency centres.
